ATYR1940 safety and biological activity assessed in early-onset Facioscapulohumeral Muscular Dystrophy patients

Facioscapulohumeral Muscular Dystrophy (FSHD) is a progressive genetic muscle disorder characterized by asymmetric muscle weakness and atrophy, primarily affecting the face, shoulders, and upper arms. It is caused by the aberrant expression of the DUX4 gene. Currently, there are no approved disease-modifying therapies for FSHD, with management largely focused on supportive care to alleviate symptoms and improve quality of life. This significant unmet medical need drives research into novel therapeutic approaches like ATYR1940, which aims to address the underlying pathology or mitigate disease progression.

This open-label extension study (NCT02531217) evaluates ATYR1940 in adult participants, aged 18 to 65 years, with an established, genetically-confirmed diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD). Participants previously enrolled in study ATYR1940-C-002 were eligible. The primary objective is to assess the safety and biological activity of ATYR1940, with secondary objectives including long-term tolerability and systemic exposure. Specific dosing, route, and frequency details are not provided in this abstract, as it focuses on the study's purpose.

This abstract describes a study protocol, and specific efficacy or safety results are not yet available. The primary objective is to evaluate the safety and biological activity of ATYR1940 in participants with early-onset FSHD, building upon previous participation in study ATYR1940-C-002. The study aims to gather long-term data on tolerability and systemic exposure, which are crucial for advancing ATYR1940 through clinical development.

The study's core finding will be the comprehensive safety profile and any preliminary indicators of biological activity observed in this patient cohort.